Trusted Resources: Education
Scientific literature and patient education texts
Management of Corneal Clouding in Patients With Mucopolysaccharidosis
source: Journal of clinical medicine
year: 2021
authors: McGrath O,Au L,Ashworth J
summary/abstract:Mucopolysaccharidoses (MPS) are a rare group of lysosomal storage disorders characterized by the accumulation of incompletely degraded glycosaminoglycans (GAGs) in multiple organ systems including the eye. Visual loss occurs in MPS predominantly due to corneal clouding and retinopathy, but the sclera, trabecular meshwork and optic nerve may all be affected. Despite the success of therapies such as enzyme replacement therapy (ERT) and hematopoietic stem-cell transplantation (HSCT) in improving many of the systemic manifestations of MPS, their effect on corneal clouding is minimal. The only current definitive treatment for corneal clouding is corneal transplantation, usually in the form of a penetrating keratoplasty or a deep anterior lamellar keratoplasty. This article aims to provide an overview of corneal clouding, its current clinical and surgical management, and significant research progress.
organization: Manchester Royal Eye Hospital, Central Manchester University Hospitals NHS Foundation Trust, Oxford Road, Manchester M13 9WL, UK.DOI: 10.3390/jcm10153263
read more
Related Content
-
Corneal Cloudiness: A Presenting Feature of Mucopolysaccharidosis Type IA 10-y-old ‘short-statured’ male pre...
-
Glaucoma in MucopolysaccharidosesMucopolysaccharidoses are a group of lys...
-
Expanding the Phenotype of Mucopolysaccharidosis Type II RetinopathyPurpose: To report novel retinal finding...
-
Increased Choroidal Thickness in Morquio SyndromeThe purpose of this clinical case report...
-
Detailed Pedigree Analyses and Prenatal Diagnosis for a Family With Mucopolysaccharidosis Type IIMucopolysaccharidosis type II (MPS II) i...
-
Awake Airway Endoscopy in Mucopolysaccharidosis: A Case ReportMucopolysaccharidosis (MPS) are a group ...
-
Oral Treatment for Mucopolysaccharidosis VI: Outcomes of the First Phase Iia Study With OdiparcilMucopolysaccharidosis (MPS) disorders ar...